Opportunities to avert health care's 'perfect storm'

Article

The "perfect storm" in health care is on its way, according to Paul Lee, MD, JD, Duke University, Durham, NC, as he described areas where research and potential paradigm changes can contribute to meeting society's needs to enhance vision, maintain wellness, and prevent vision loss. Dr. Lee delivered a keynote address entitled "Future challenges and opportunities in eye research and the aging population" during The Association for Research in Vision and Ophthalmology (ARVO)/Alcon keynote session Sunday evening.

The "perfect storm" in health care is on its way, according to Paul Lee, MD, JD, Duke University, Durham, NC, as he described areas where research and potential paradigm changes can contribute to meeting society's needs to enhance vision, maintain wellness, and prevent vision loss. Dr. Lee delivered a keynote address entitled "Future challenges and opportunities in eye research and the aging population" during The Association for Research in Vision and Ophthalmology (ARVO)/Alcon keynote session Sunday evening.

"Vision is very important to all of us," Dr. Lee said. "As our vision deteriorates, we have more limitations in our activities of daily living and in our instrumental activities. Economic and social support factors can help mitigate the impact of visual problems. The United Nations Research Plan on Aging explicitly acknowledges the importance of including disciplines such as political science, economics, psychology, and sociology in helping us understand aging and how to provide better lives for us as we get older."

With that statement, Dr. Lee set the stage to outline his views of opportunities that exist to avert the perfect storm that is on the horizon.

Dr. Lee cited four factors that herald the coming crisis in health care: an explosion and demand for high-quality health care without the foreseeable infrastructure growth in money, personnel, and systems to meet that demand; increasing costs that will conflict with other societal resources such as the war in Iraq, national security, and education; insufficient health-care providers by 2020 without any changes in the current practices; and system performance concerns, i.e., gaps in providing adequate annual health care despite the presence of health insurance.

"What can be done?" Dr. Lee asked. He recommended changing the paradigms and asking the basic questions in order to question the existing assumptions about every facet of the health-care delivery system, namely, "Why should we care, when should we intervene, what should we be doing, and who and where should things be done?"

Solving the problems of health care will depend on three key elements: staying healthy, prevention, and chronic disease management.

"When we look at the paradigms, we need to determine how we can integrate all of these into a comprehensive approach," Dr. Lee commented. He said that innovative research into the impact of such things as, for example, different sites of care, home self-testing, and less expensive/less office-based interventions is needed as well as cooperation among a number of experts to meet the goal of improved health care.

"We can only be successful by relying on research from dedicated health-care providers," Dr. Lee concluded. "We cannot keep on in the same vein. We need to work together to come up with the necessary innovations to ensure that all of us will have more years and better years ahead of us."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.